Loading
HCC Hepatocellular Carcinoma / CRC (colorectal Cancer) / Gastric Carcinoma · Observational Study
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned observational study using immunohistochemistry to profile ENPP1/cGAS co-expression and stromal FAP expression across eight solid tumor types in Vietnamese patients. The study is recruiting and has not yet reported results; it is designed to characterize prevalence of biomarker expression at baseline, not to test clinical hypotheses or treatment effects.
Observational. HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer, Lung Cancer, Endometrial Cancer, Melanoma (Skin Cancer), Pancreatic…; age from 18 Years. Intervention: Patients with malignant solid tumors. n = 162. 2 sites: Vietnam.
This is a planned observational study using immunohistochemistry to profile ENPP1/cGAS co-expression and stromal FAP expression across eight solid tumor types in Vietnamese patients. The study is recruiting and has not yet reported results; it is designed to characterize prevalence of biomarker expression at baseline, not to test clinical hypotheses or treatment effects.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This descriptive study will establish baseline prevalence of ENPP1/cGAS and FAP expression in Asian solid tumors, but without results or clinical outcome correlation, it cannot yet inform clinical decision-making or biomarker utility.
This is an active observational registry study examining immunohistochemical expression profiles in archived tumor samples; no results are posted, making it a descriptive baseline assessment that cannot yet support clinical or mechanistic conclusions.
As stated by the source record.
Quoted from the source exactly as published.
This descriptive study will establish baseline prevalence of ENPP1/cGAS and FAP expression in Asian solid tumors, but without results or clinical outcome correlation, it cannot yet inform clinical decision-making or biomarker utility.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07808164). This is a study registration, not published results. Lead sponsor: Tam Anh Research Institute. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 162 participants (ESTIMATED). Conditions: HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer, Lung Cancer, Endometrial Cancer, Melanoma (Skin Cancer), Pancreatic Cancer. Interventions: OTHER: IHC analysis for ENPP1, cGAS, and FAP expression. Primary outcome measures: Prevalence of EG+ phenotype (ENPP1/cGAS co-expression) and stromal FAP expression , At baseline. Brief summary: This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor samples using immunohistochemistry (IHC). The study involves no investigational treatments or participant-facing procedures. Tumor samples used in this study consist exclusively of archived formalin-fixed paraffin- embedded (FFPE) tumor samples that were collected as part of routine clinical diagnosis or treatment and for which all required procedures for standard clinical care have been completed. Only archived tumor samples obtained from routine clinical care will be included in this study. No additional biopsy, surgical resection, or specimen collection will be performed for research purposes, and no sample will be diverted prior to completion of clinical requirements. All included archived tumor samples will undergo ENPP1, cGAS, and FAP IHC analysis according to the procedures specified in the Laboratory Manual.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.